Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Xicota Vila, Laura, 1987-ca
- dc.contributor.author Rodríguez-Morató, Jose, 1987-ca
- dc.contributor.author Dierssen, Maraca
- dc.contributor.author Torre Fornell, Rafael de laca
- dc.date.accessioned 2017-03-15T08:40:58Z
- dc.date.issued 2017
- dc.description.abstract Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects.ca
- dc.description.sponsorship This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010- 19434, MTM2012-38067-C02-01 and SAF2013-49129-C1- R), EU (Era Net Neuron PCIN-2013-060) co-financed by European Regional Development Fund, DIUE de la Generalitat de Catalunya (SGR 2009/1450, SGR 2014/464 SGR 2014/1125). We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208.Jose Rodríguez-Morató was supported by a FI-DGR 2013 predoctoral fellowship from the Generalitat de Catalunya.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. Curr Drug Targets. 2017;18(2):174-195. DOI: 10.2174/1389450116666150825113655ca
- dc.identifier.doi http://dx.doi.org/10.2174/1389450116666150825113655
- dc.identifier.issn 1389-4501
- dc.identifier.uri http://hdl.handle.net/10230/28231
- dc.language.iso engca
- dc.publisher Bentham Science Publishersca
- dc.relation.ispartof Current Drug Targets. 2017;18(2):174-95
- dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2010-19434
- dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/MTM2012-38067-C02-01
- dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2013-49129-C1-R
- dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/PCIN-2013-060
- dc.rights © Bentham Science Publishers. Article published in Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R, Current Drug Targets. 2017;18(2):174-195. The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/10.2174/1389450116666150825113655ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.other Alzheimer, Malaltia d'ca
- dc.subject.other Sistema nerviós -- Degeneracióca
- dc.title Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Diseaseca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/acceptedVersionca